Document Detail

Metastasis-Initiating Cells in Renal Cancer.
MedLine Citation:
PMID:  25152705     Owner:  NLM     Status:  Publisher    
Metastasis is a complex process that propagates cells from the primary or initial site of the cancer occurrence to distant parts of the body. Cancer cells break from the cancer site and circulate through the bloodstream or lymph vessels, allowing them to reach nearly all parts of the body. These circulating tumour cells (CTCs) contain specialized metastasis-initiating cells (MICs) that reside in the biological heterogeneous primary tumour. Researchers have hypothesized that metastasis of renal cell carcinoma is initiated by circulation of MICs in patients' blood and bone marrow. Based on the cancer stem/progenitor cell concept of carcinogenesis, understanding the molecular phenotypes of metastasis-initiating cells (MICs) in renal cancer could play a vital role in developing strategies for therapeutic interventions in renal cancer. Existence of MICs among CTCs in renal carcinoma has not been proven in large scale. However, some studies have reported that specialized markers are found on the surface of circulating cells from the primary tumour. In mice, MICs have been isolated from CTCs using such markers, which have then been transplanted into xenograft model to show whether they give rise to metastasis in different organs. Considering these findings, in this review we have attempted to summarize the studies connected with MICs and their gene expression profiles that are responsible for metastasis in renal cancer.
Mohammed I Khan; Anna M Czarnecka; Renata Duchnowska; Wojciech Kukwa; Cezary Szczylik
Related Documents :
10598365 - Hormone replacement and breast cancer: implications of the iowa women's health study.
10348095 - The treatment of advanced prostate cancer with ketoconazole: safety issues.
24664305 - Update of molecular pathobiology in oral cancer: a review.
16684425 - Effect of a new leuprorelin formulation on testosterone levels in patients with advance...
15753355 - Circumventing multidrug resistance in cancer by beta-galactoside binding protein, an an...
14710385 - Results of clinical trials of multimodality therapy for resectable nonsmall-cell lung c...
Publication Detail:
Journal Detail:
Title:  Current signal transduction therapy     Volume:  8     ISSN:  1574-3624     ISO Abbreviation:  Curr Signal Transduct Ther     Publication Date:  2014 Dec 
Date Detail:
Created Date:  2014-8-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101273157     Medline TA:  Curr Signal Transduct Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  240-246     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma...
Next Document:  Lower expressions of the human bitter taste receptor TAS2R in smokers: reverse transcriptase-polymer...